



Global Health EDCTP3 Joint Undertaking

56 – 60 Avenue de la Toison d’Or

1060 Brussels

Belgium

August 28, 2025

Letter of endorsement

Dear Sir/Madam,

On behalf of University of Navarra, Campus Universitario s/n, 31008, Pamplona, Spain, with VAT number ES R3168001J and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

The University of Navarra (UNAV) is a non-profit private university with more than 13,600 students (28% internationals) based in Pamplona, Spain. It confers 56 official degrees and administers more than 90 postgraduate programs (including 22 doctoral programs and 38 master's programs) through 10 schools, two superior colleges, the IESE Business School, the ISSA, and other centres and institutions. Among other recognitions, it has been rated as the most international of Spanish Universities according to the CYD ranking, it is among the top 100 universities in the world in 6 areas of the QS ranking.

The Institute for Culture and Society (ICS) is the research center for Humanities and Social Sciences at the University of Navarra. Founded in 2010, its mission is to generate interdisciplinary knowledge to address major societal challenges through a rigorous, scientific, and humanistic approach. The ICS brings together over 80 researchers from diverse disciplines and nationalities, organized into specialized groups that explore key areas such as human dignity, social coexistence, aging, palliative care, emotional culture, public discourse, cultural creativity, and spirituality.

Dr. Carlos Chaccour is a member of the ICS-Navarra Center for International Development. He is Global health innovator and clinical trialist, with experience managing complex research programs from conception to implementation across challenging environments with an emphasis on malaria and NTDs. Dr. Chaccour has ample experience overseeing large, multi-disciplinary teams in multi-cultural environments to deliver actionable results to inform local and global policy and has worked for health-startups and large global health programs, both locally and at WHO-level. He is committed to uncover the vocation of the next generation of global health actors by applying innovation to improve healthcare, particularly among vulnerable and underserved populations in LMIC.

The UNAV contribution to SINCEP-Africa will be led by Dr. Chaccour and his team, who will engage with those at the forefront of the clinical, research and capacity building expertise of the university to ensure that program leverages the full capacity of the UNAV to contribute to the program goals. Our proposed



engagement is to lead or co-lead WP5 “Clinical research and trial management”, WP8 “Capacity strengthening and training” or WP4 “Ethics, regulatory and pharmacovigilance”.

Our contributions to the Global Health EDCTP3 JU will be done in the framework of the SINCEP-Africa project. UNAV will provide expertise on conducting ICH-grade large scale clinical trials for global health drugs or vector control products based on the lessons learned during the implementation of the “Cost effectiveness evaluation of vector control tools in Mozambique”, the BOHEMIA trials in Mozambique, Tanzania and Kenya as well as the ELIKIA project in DRC. Beyond the designated budget, we expect to contribute in-kind with project management, expert-time and partly waiving training fees for an estimated value of 30.000 Euros per year.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorized by Global Health EDCTP3 JU. Internal dissemination of information within our organization will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

31850624V
FRANCISCO
JAVIER MATA
(R: R3168001J)

Firmado digitalmente por 31850624V
FRANCISCO JAVIER MATA (R: R3168001J)
Nombre de reconocimiento (DN):
2.5.4.13=RefAEAT/AEAT0398/PUESTO
1/53647/24062025100935,
serialNumber=IDCES-31850624V,
givenName=FRANCISCO JAVIER,
sn=MATA RODRIGUEZ, cn=31850624V
FRANCISCO JAVIER MATA (R: R3168001J),
2.5.4.97=VATES-R3168001J,
o=UNIVERSIDAD DE NAVARRA, c=ES
Fecha: 2025.08.28 08:40:57 +02'00'

Javier Mata Rodriguez, Director of the Research Management Service